Dr Laura Price is a consultant respiratory physician at Royal Brompton Hospital, where she treats private and NHS patients.

She studied at the University of Bristol, graduating in 1998, having obtained an intercalated BSc in cellular and molecular pathology in 1995. 

Further to her specialist experience in pulmonary hypertension, Dr Price has broad training in general, respiratory and critical care medicine. She also has experience in anaesthesia, obtaining her primary Fellowship of the Royal College of Anaesthetists (FRCA) in earlier training posts. 

She undertook specialist training in respiratory and general medicine on the North West London rotation between 2005 and 2013. During this time, she gained a PhD in pulmonary hypertension from Imperial College London. In 2008, she spent 12 months in the largest pulmonary hypertension centre in Europe (in Paris, France), obtaining advanced clinical and research experience in the condition. 

Clinical expertise

Dr Laura Price is an integral member of the National Pulmonary Hypertension Service at Royal Brompton Hospital, consulting with patients who have this condition and other pulmonary vascular diseases. 

She has special interests in:

She also runs outpatient pulmonary hypertension clinics, and supervises care of inpatients with the condition with emergencies relating to pulmonary hypertension or co-existing medical conditions.

With haematology colleagues, Dr Price is setting up a new service following up patients after pulmonary emboli at Royal Brompton Hospital. 

Research interests

Dr Laura Price’s particular areas of research include: 

Among several ongoing clinical projects, she is co-applicant on a National Institute for Health Research (NIHR) application to study the benefits of specific drugs in patients with COPD, and is co-supervising an MD-Res student examining the power of serial change in non-invasive surrogates of pulmonary hypertension in patients with interstitial lung disease. 

During her PhD studentship, Dr Price demonstrated that activation of the key inflammatory signalling molecule, NF-kappa B, was enhanced in lungs from patients with idiopathic pulmonary arterial hypertension. 

Further work using corticosteroids in a disease model and in relevant lung cells showed that suppression of inflammation in pulmonary arterial hypertension might be a potential therapeutic target. Her PhD led to four well-cited peer-reviewed publications.  


Dr Laura Price has over 15 years of experience in undergraduate and postgraduate teaching.

She is also an honorary clinical senior lecturer at the National Heart and Lung Institute at Imperial College London.


Dr Laura Price has written over 30 peer-reviewed articles, across a wide range of topics in respiratory disease (notably related to pulmonary hypertension and critical care), as well as authoring many book chapters.